OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling.
The molecular heterogeneity of human tumors challenges the development of effective preventive and therapeutic strategies. To overcome this issue, a rational approach is the concomitant targeting of clinically relevant cellular abnormalities with combination therapy or a potent multi-targeted agent. OSU-A9 is a novel indole-3-carbinol derivative that retains the parent compound's ability to perturb multiple components of oncogenic signaling, but provides marked advantages in chemical stability and antitumor potency. Here, we show that OSU-A9 exhibits two orders of magnitude greater potency than indole-3-carbinol in inducing apoptosis in various breast cancer cell lines with distinct genetic abnormalities, including MCF-7, MDA-MB-231 and SKBR3, with the half maximal inhibitory concentration in the range of 1.2-1.8 microM vis-à-vis 200 microM for indole-3-carbinol. This differential potency was paralleled by OSU-A9's superior activity against multiple components of the Akt-nuclear factor-kappa B (NF-kappaB) and stress response signaling pathways. Notable among these were the increased estrogen receptor (ER)-beta/ERalpha expression ratio, reduced expression of HER2 and CXCR4 and the upregulation of aryl hydrocarbon receptor expression and its downstream target NF-E2 p45-regulated factor (Nrf2). Non-malignant MCF-10A cells were resistant to OSU-A9's antiproliferative effects. Daily oral administration of OSU-A9 at 25 and 50 mg/kg for 49 days significantly inhibited MCF-7 tumor growth by 59 and 70%, respectively, without overt signs of toxicity or evidence of induced hepatic biotransformation enzymes. In summary, OSU-A9 is a potent, orally bioavailable inhibitor of the Akt-NF-kappaB signaling network, targeting multiple aspects of breast tumor pathogenesis and progression. Thus, its translational potential for the treatment or prevention of breast cancer warrants further investigation.
Weng
Jing-Ru
JR
Department of Biological Science and Technology, China Medical University, Taichung, Taiwan.
Tsai
Chen-Hsun
CH
Omar
Hany A
HA
Sargeant
Aaron M
AM
Wang
Dasheng
D
Kulp
Samuel K
SK
Shapiro
Charles L
CL
Chen
Ching-Shih
CS
D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology / Q000517:prevention & control; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D047628:Estrogen Receptor alpha / Q000187:drug effects / Q000235:genetics; D047629:Estrogen Receptor beta / Q000187:drug effects / Q000235:genetics; D005260:Female; D017930:Genes, Reporter; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D008156:Luciferases / Q000235:genetics; D000432:Methanol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D016328:NF-kappa B / Q000502:physiology*; D051057:Proto-Oncogene Proteins c-akt / Q000187:drug effects / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
C523234:(1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl)-methanol; D000970:Antineoplastic Agents; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D007211:Indoles; D016328:NF-kappa B; D008156:Luciferases; D051057:Proto-Oncogene Proteins c-akt; D000432:Methanol
Nature. 2005 Oct 13;437(7061):942-3
16222266
J Nutr Biochem. 2005 Feb;16(2):65-73
15681163
Cancer Res. 2003 Jul 15;63(14):4028-36
12874002
Cancer Res. 2007 Jan 15;67(2):674-83
17234778
Cancer Cell. 2004 Nov;6(5):459-69
15542430
Mol Carcinog. 2006 Jun;45(6):355-61
16673382
J Med Chem. 2007 Jul 26;50(15):3412-5
17602463
Cell Res. 2005 Jan;15(1):11-8
15686620
J Nutr. 2003 Jul;133(7 Suppl):2470S-2475S
12840226
Cancer Res. 2006 Jun 1;66(11):5665-75
16740704
Cancer Detect Prev. 2004;28(1):72-9
15041081
J Steroid Biochem Mol Biol. 2002 Aug;81(4-5):327-32
12361722
J Biol Chem. 2003 Jun 13;278(24):21631-8
12690099
Endocrinology. 2001 Sep;142(9):4120-30
11517191
Cancer Res. 2005 Aug 1;65(15):6557-67
16061635
Clin Cancer Res. 2002 Apr;8(4):1228-36
11948137
Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2477-81
17164373
Cancer Res. 2005 Nov 1;65(21):9891-8
16267013
Eur J Cancer. 2005 Sep;41(13):1842-53
16087329
In Vivo. 2006 Mar-Apr;20(2):221-8
16634522
Mol Cancer Ther. 2006 Nov;5(11):2747-56
17121921
Science. 1989 May 12;244(4905):707-12
2470152
Cell Res. 2005 Jan;15(1):36-42
15686625
Br J Cancer. 2006 Feb 13;94(3):407-26
16434996
Carcinogenesis. 2004 Nov;25(11):2257-64
15240508
Cancer Res. 2000 Oct 1;60(19):5390-4
11034077
J Biol Chem. 2005 May 27;280(21):20340-8
15790560
Cell Cycle. 2005 Sep;4(9):1201-15
16082211
Endocr Relat Cancer. 2003 Jun;10(2):193-202
12790782
Toxicol Appl Pharmacol. 2006 Mar 1;211(2):115-23
16043203
N Engl J Med. 1997 May 15;336(20):1401-8
9145676
Biochem Pharmacol. 2006 Sep 28;72(7):795-805
16780804
Biochem Pharmacol. 2007 Jun 15;73(12):1853-62
17266942
Cancer Lett. 2008 Apr 18;262(2):153-63
18314259
Exp Cell Res. 2004 Nov 1;300(2):427-39
15475007
J Nutr Biochem. 2006 Oct;17(10):659-64
16488130
Nutr Cancer. 2004;48(1):84-94
15203382
Mol Cell Biol. 2001 Feb;21(4):1249-59
11158311
Annu Rev Pharmacol Toxicol. 1991;31:253-87
2064376
Am J Surg Pathol. 2003 Dec;27(12):1502-12
14657709
Cancer Res. 2007 Aug 15;67(16):7815-24
17699787
Toxicol Sci. 2008 Oct;105(2):303-11
18644836
Toxicol Pathol. 2007 Jun;35(4):549-61
17562488
Cancer Res. 2005 Feb 1;65(3):967-71
15705897
Cell Death Differ. 2004 Apr;11(4):381-9
14685163
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S37-46
16113098
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1953-60
16103443
Nucleic Acids Res. 2006 Mar 06;34(5):1416-26
16522651
J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65
12237281
Cancer Res. 2006 Jan 1;66(1):412-8
16397256